The Thiol-polyamine Metabolism of Trypanosoma cruzi: Molecular Targets and Drug Repurposing Strategies

Author(s): Alan Talevi, Carolina Carrillo, Marcelo Comini*.

Journal Name: Current Medicinal Chemistry

Volume 26 , Issue 36 , 2019


Chagas´ disease continues to be a challenging and neglected public health problem in many American countries. The etiologic agent, Trypanosoma cruzi, develops intracellularly in the mammalian host, which hinders treatment efficacy. Progress in the knowledge of parasite biology and host-pathogen interaction has not been paralleled by the development of novel, safe and effective therapeutic options. It is then urgent to seek for novel therapeutic candidates and to implement drug discovery strategies that may accelerate the discovery process. The most appealing targets for pharmacological intervention are those essential for the pathogen and, whenever possible, absent or significantly different from the host homolog. The thiol-polyamine metabolism of T. cruzi offers interesting candidates for a rational design of selective drugs. In this respect, here we critically review the state of the art of the thiolpolyamine metabolism of T. cruzi and the pharmacological potential of its components. On the other hand, drug repurposing emerged as a valid strategy to identify new biological activities for drugs in clinical use, while significantly shortening the long time and high cost associated with de novo drug discovery approaches. Thus, we also discuss the different drug repurposing strategies available with a special emphasis in their applications to the identification of drug candidates targeting essential components of the thiol-polyamine metabolism of T. cruzi.

Keywords: Therapy, trypanothione, spermidine, polyamines, Chagas´ disease, bioinformatics, screening, approved drugs, drug repositioning, drug repurposing.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2019
Page: [6614 - 6635]
Pages: 22
DOI: 10.2174/0929867325666180926151059
Price: $95

Article Metrics

PDF: 4